Metabolic Risk Contributes to Diabetes Onset in People With HIV
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 7, 2024 -- For people with HIV (PWH) with low-to-moderate atherosclerotic cardiovascular disease (ASCVD) risk, metabolic risk factors contribute to new-onset diabetes mellitus (DM) among those treated with pitavastatin or placebo, according to a study published online Oct. 8 in the Annals of Internal Medicine.
Kathleen V. Fitch, from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues examined the contribution of known DM risk factors to excess risk for DM with pitavastatin use among PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial. Participants included 7,731 PWH aged 40 to 75 years with a low-to-moderate risk for ASCVD, without DM at study entry, who were randomly assigned to pitavastatin 4 mg daily or placebo in a 1:1 ratio.
The researchers found that in each treatment group, participants with at least three DM risk factors versus no risk factors had an increased risk for DM (incidence rate, 3.24 versus 0.34 per 100 person-years in the pitavastatin group and 2.66 versus 0.27 per 100 person-years in the placebo group). The highest incidence of DM was seen in South Asia. High body mass index, prediabetes, and metabolic syndrome components were strongly associated with new-onset DM in adjusted analyses.
"Together these data suggest the importance of implementing comprehensive risk reduction strategies for PWH with risk factors for DM, including dietary and exercise interventions," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.